|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386.
2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Eckert AW, Wickenhauser C, Salins PC,
Kappler M, Bukur J and Seliger B: Clinical relevance of the tumor
microenvironment and immune escape of oral squamous cell carcinoma.
J Transl Med. 14(85)2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Lo HW and Hung MC: Nuclear EGFR signalling
network in cancers: Linking EGFR pathway to cell cycle progression,
nitric oxide pathway and patient survival. Br J Cancer. 94:184–188.
2006.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Yarden Y: Grundlagen der
Signaltransduktion. Onkologie. 28 (Suppl 4):S14–S17. 2005.(In
German). PubMed/NCBI View Article : Google Scholar
|
|
5
|
Christensen A, Kiss K, Lelkaitis G, Juhl
K, Persson M, Charabi BW, Mortensen J, Forman JL, Sørensen AL,
Jensen DH, et al: Urokinase-type plasminogen activator receptor
(uPAR), tissue factor (TF) and epidermal growth factor receptor
(EGFR): Tumor expression patterns and prognostic value in oral
cancer. BMC Cancer. 17(572)2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Bossi P, Resteghini C, Paielli N, Licitra
L, Pilotti S and Perrone F: Prognostic and predictive value of EGFR
in head and neck squamous cell carcinoma. Oncotarget.
7:74362–74379. 2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Søland TM and Brusevold IJ: Prognostic
molecular markers in cancer-quo vadis? Histopathology. 63:297–308.
2013.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia
W, Wei Y, Bartholomeusz G, Shih JY and Hung MC: Nuclear interaction
of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer
Cell. 7:575–589. 2005.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Marti U, Burwen SJ, Wells A, Barker ME,
Huling S, Feren AM and Jones AL: Localization of epidermal growth
factor receptor in hepatocyte nuclei. Hepatology. 13:15–20.
1991.PubMed/NCBI
|
|
10
|
Lo HW, Xia W, Wei Y, Ali-Seyed M, Huang SF
and Hung MC: Novel prognostic value of nuclear epidermal growth
factor receptor in breast cancer. Cancer Res. 65:338–348.
2005.PubMed/NCBI
|
|
11
|
Taguchi T: Nuclear translocation of
epidermal growth factor receptor and its relation to
clinicopathological factors in oral squamous cell carcinomas.
Kokubyo Gakkai Zasshi. 81:45–52. 2014.(In Japanese). PubMed/NCBI
|
|
12
|
Maramotti S, Paci M, Manzotti G, Rapicetta
C, Gugnoni M, Galeone C, Cesario A and Lococo F: Soluble epidermal
growth factor receptors (sEGFRs) in cancer: Biological aspects and
clinical relevance. Int J Mol Sci. 17(593)2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Weinholdt C, Wichmann H, Kotrba J, Ardell
DH, Kappler M, Eckert AW, Vordermark D and Grosse I: Prediction of
regulatory targets of alternative isoforms of the epidermal growth
factor receptor in a glioblastoma cell line. BMC Bioinformatics.
20(434)2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Eckert AW, Lautner MH, Schütze A, Taubert
H, Schubert J and Bilkenroth U: Coexpression of hypoxia-inducible
factor-1α and glucose transporter-1 is associated with poor
prognosis in oral squamous cell carcinoma patients. Histopathology.
58:1136–1147. 2011.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Eckert AW, Schutze A, Lautner MH, Taubert
H, Schubert J and Bilkenroth U: HIF-1alpha is a prognostic marker
in oral squamous cell carcinomas. Int J Biol Markers. 25:87–92.
2010.PubMed/NCBI
|
|
16
|
Wichmann H, Güttler A, Bache M, Taubert H,
Rot S, Kessler J, Eckert AW, Kappler M and Vordermark D: Targeting
of EGFR and HER2 with therapeutic antibodies and siRNA: A
comparative study in glioblastoma cells. Strahlenther Onkol.
191:180–191. 2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Remmele W and Stegner HE: Vorschlag zur
einheitlichen definition eines immunreaktiven score (IRS) für den
immunhistochemischen ostrogenrezeptor-nachweis (ER-ICA) im
mammakarzinomgewebe. Pathologe. 8:138–140. 1987.
|
|
18
|
Kimura I, Kitahara H, Ooi K, Kato K,
Noguchi N, Yoshizawa K, Nakamura H and Kawashiri S: Loss of
epidermal growth factor receptor expression in oral squamous cell
carcinoma is associated with invasiveness and
epithelial-mesenchymal transition. Oncol Lett. 11:201–207.
2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Rot S, Taubert H, Bache M, Greither T,
Würl P, Holzhausen HJ, Eckert AW, Vordermark D and Kappler M: Low
HIF-1α and low EGFR mRNA expression significantly associate with
poor survival in soft tissue sarcoma patients; the proteins react
differently. Int J Mol Sci. 19(3842)2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Greither T, Koser F, Holzhausen HJ,
Güttler A, Würl P, Kappler M, Wach S and Taubert H: MiR-155-5p and
MiR-203a-3p are prognostic factors in soft tissue sarcoma. Cancers
(Basel). 12(2254)2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Sigismund S, Avanzato D and Lanzetti L:
Emerging functions of the EGFR in cancer. Mol Oncol. 12:3–20.
2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Ryott M, Wangsa D, Heselmeyer-Haddad K,
Lindholm J, Elmberger G, Auer G, Avall Lundqvist E, Ried T and
Munck-Wikland E: EGFR protein overexpression and gene copy number
increases in oral tongue squamous cell carcinoma. Eur J Cancer.
45:1700–1708. 2009.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Diniz-Freitas M, García-Caballero T,
Antúnez-López J, Gándara-Rey JM and García-García A:
Pharmacodiagnostic evaluation of EGFR expression in oral squamous
cell carcinoma. Oral Dis. 13:285–290. 2007.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Shah NG, Trivedi TI, Tankshali RA, Goswami
JV, Jetly DH, Shukla SN, Shah PM and Verma RJ: Prognostic
significance of molecular markers in oral squamous cell carcinoma:
A multivariate analysis. Head Neck. 31:1544–1556. 2009.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Monteiro LS, Diniz-Freitas M,
Garcia-Caballero T, Warnakulasuriya S, Forteza J and Fraga M:
Combined cytoplasmic and membranous EGFR and p53 overexpression is
a poor prognostic marker in early stage oral squamous cell
carcinoma. J Oral Pathol Med. 41:559–567. 2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Huang SF, Cheng SD, Chien HT, Liao CT,
Chen IH, Wang HM, Chuang WY, Wang CY and Hsieh LL: Relationship
between epidermal growth factor receptor gene copy number and
protein expression in oral cavity squamous cell carcinoma. Oral
Oncol. 48:67–72. 2012.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Maiorano E, Favia G, Maisonneuve P and
Viale G: Prognostic implications of epidermal growth factor
receptor immunoreactivity in squamous cell carcinoma of the oral
mucosa. J Pathol. 185:167–174. 1998.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Yang CC, Lin LC, Lin YW, Tian YF, Lin CY,
Sheu MJ, Li CF and Tai MH: Higher nuclear EGFR expression is a
better predictor of survival in rectal cancer patients following
neoadjuvant chemoradiotherapy than cytoplasmic EGFR expression.
Oncol Lett. 17:1551–1558. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Lo HW, Hsu SC and Hung MC: EGFR signaling
pathway in breast cancers: From traditional signal transduction to
direct nuclear translocalization. Breast Cancer Res Treat.
95:211–218. 2006.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Takei J, Kaneko MK, Ohishi T, Kawada M,
Harada H and Kato Y: A novel anti-EGFR monoclonal antibody
(EMab-17) exerts antitumor activity against oral squamous cell
carcinomas via antibody-dependent cellular cytotoxicity and
complement-dependent cytotoxicity. Oncol Lett. 19:2809–2816.
2020.PubMed/NCBI View Article : Google Scholar
|
